These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
588 related articles for article (PubMed ID: 31051197)
1. Targeting opioid dysregulation in depression for the development of novel therapeutics. Browne CA; Lucki I Pharmacol Ther; 2019 Sep; 201():51-76. PubMed ID: 31051197 [TBL] [Abstract][Full Text] [Related]
3. Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine. Adzic M; Lukic I; Mitic M; Glavonic E; Dragicevic N; Ivkovic S Life Sci; 2023 Aug; 326():121803. PubMed ID: 37245840 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094). Witkin JM; Wallace TL; Martin WJ Handb Exp Pharmacol; 2019; 254():399-415. PubMed ID: 30701317 [TBL] [Abstract][Full Text] [Related]
5. The NOP antagonist BTRX-246040 increases stress resilience in mice without affecting adult neurogenesis in the hippocampus. D'Oliveira da Silva F; Azevedo Neto J; Sturaro C; Guarino A; Robert C; Gavioli EC; Calo G; Mouledous L; Ruzza C Neuropharmacology; 2022 Jul; 212():109077. PubMed ID: 35513173 [TBL] [Abstract][Full Text] [Related]
6. The opioid system in depression. Jelen LA; Stone JM; Young AH; Mehta MA Neurosci Biobehav Rev; 2022 Sep; 140():104800. PubMed ID: 35914624 [TBL] [Abstract][Full Text] [Related]
7. Modulation of the central opioid system as an antidepressant target in rodent models. McHugh KL; Kelly JP Prog Brain Res; 2018; 239():49-87. PubMed ID: 30314569 [TBL] [Abstract][Full Text] [Related]
8. Label-free cell phenotypic study of opioid receptors and discovery of novel mu opioid ligands from natural products. Hou T; Xu F; Peng X; Zhou H; Zhang X; Qiu M; Wang J; Liu Y; Liang X J Ethnopharmacol; 2021 Apr; 270():113872. PubMed ID: 33485984 [TBL] [Abstract][Full Text] [Related]
11. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors. Olianas MC; Concas D; Onali P Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046 [TBL] [Abstract][Full Text] [Related]
12. Opioid Mechanisms and the Treatment of Depression. Jelen LA; Young AH; Mehta MA Curr Top Behav Neurosci; 2024; 66():67-99. PubMed ID: 37923934 [TBL] [Abstract][Full Text] [Related]
13. Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders. Reed B; Butelman ER; Kreek MJ Handb Exp Pharmacol; 2022; 271():473-491. PubMed ID: 33174064 [TBL] [Abstract][Full Text] [Related]